Active salvage chemotherapy versus best supportive care for patients with recurrent or metastatic squamous cell carcinoma of the esophagus refractory or intolerable to fluorouracil, platinum, and taxane-Reference-Cited by-同舟云学术

Active salvage chemotherapy versus best supportive care for patients with recurrent or metastatic squamous cell carcinoma of the esophagus refractory or intolerable to fluorouracil, platinum, and taxane

Published:2016-10-24 Issue:6 Volume:78 Page:1209-1216
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Nomura Motoo,Iwasa Satoru,Tsushima Takahiro,Kato Ken,Yasui Hirofumi,Boku Narikazu,Muto Manabu,Muro Kei

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-016-3179-3.pdf

Reference28 articles.

1. International Agency for Research on Cancer; GLOBOCAN 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx

2. Tachimori Y, Ozawa S, Numasaki H et al (2015) Comprehensive registry of esophageal cancer in Japan, 2008. Esophagus 12:130–157

3. Hayashi K, Ando N, Watanabe H et al (2001) Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 31:419–423

4. Thallinger CM, Raderer M, Hejna M (2011) Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol 29:4709–4714

5. Anderson SE, O’Reilly EM, Kelsen DP et al (2003) Phase II trial of 96-h paclitaxel in previously treated patients with advanced esophageal cancer. Cancer Invest 21:512–516

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 5-Fluorouracil plus L-leucovorin and oxaliplatin treatment for esophageal squamous cell carcinoma: A multicenter retrospective study;2024-06-11

2. Comparative analysis of systemic oncological treatments and best supportive care for advanced gastresophageal cancer: A comprehensive scoping review and evidence map;Journal of Evidence-Based Medicine;2023-06

3. A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404);Esophagus;2022-06-20

4. Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study;Esophagus;2022-01-20

5. A Phase II Study of Apatinib in Patients with Chemotherapy‐Refractory Esophageal Squamous Cell Carcinoma (ESO‐Shanghai 11);The Oncologist;2021-02